Healthcare Utilization and Comorbidity Burden of Pancreatic Cancer in U.S Hospitals. Analysis of a National Sample Database

Authors' Affiliations

Shahnawaz Notta DO, Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City TN. Sanku Koushik MD, Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City TN. Sudeepthi Mekala Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City TN. Mark Young MD, Department of Internal Medicine, Division of Gastroenterology, Quillen College of Medicine, East Tennessee State University, Johnson City TN.

Location

D.P. Culp Center Ballroom

Start Date

4-5-2024 9:00 AM

End Date

4-5-2024 11:30 AM

Poster Number

71

Name of Project's Faculty Sponsor

Dr. Venkata Vedantam

Faculty Sponsor's Department

Internal Medicine

Classification of First Author

Medical Resident or Clinical Fellow

Competition Type

Competitive

Type

Poster Presentation

Presentation Category

Health

Abstract or Artist's Statement

Pancreatic cancer accounts for 3% of all cancer diagnoses in the United States and is the fourth leading cause of all cancer-related causes of death in the US according to the American Cancer Society in 2023, with 5 years survival rate ranging from 5-15%.This study aims to assess the economic burden and healthcare costs associated with the diagnosis, treatment, and management of pancreatic cancer, with a focus on understanding the financial impact on patients, healthcare systems, and society at large. A population-based cross-sectional study was conducted utilizing the National Inpatient Sample Database (NIS 2016-2020). The variable of interest, pancreatic cancer, was extracted employing the 10th edition of the International Classification of Diseases (ICD-10) as the primary diagnosis for hospitalization in US healthcare facilities. Covariates considered in this study encompassed patient socio-demographics such as age, gender, and race, alongside variables related to insurance type, total charges, and mortality outcome. To ensure the representativeness of the study population, weighting was applied to align it with the broader demographics of the U.S. populace. Estimations regarding disease-related healthcare costs, length of stay, and mortality were derived through both crude and Propensity-Matched Analyses. A sample size of 33,446 patients hospitalized with pancreatic cancer as the primary diagnosis upon admission was extracted from the database. Of these, 49.72% were female, and 50.23% were male. The average age at the time of pancreatic cancer diagnosis was 68.48 years (CI 68.36-68.61). Among the patients, 70.49% were covered by Medicare/Medicaid, 27.41% had private insurance, and 2.10% were self-pay patients. The average length of stay for newly diagnosed pancreatic cancer patients was 6.96 days (CI 6.89-7.03), with average total charges amounting to $89,561 (CI $88,131.09-$90,991.40) for Medicare/Medicaid patients, $90,566 (CI $88,117.15-$93,014.89) for those with private insurance, and $75,978 (CI $69,432.38-$82,523.69) for self-pay patients. Healthcare spending for pancreatic cancer increased by 26.13% from 2016 to 2020. In conclusion, our analysis of healthcare utilization and the comorbidity burden of pancreatic cancer in U.S. hospitals has unveiled valuable insights into the challenges encountered by both patients and healthcare systems. These findings underscore the significance of implementing tailored care strategies to effectively address the multifaceted economic impact of pancreatic cancer, not only on individual patients but also on society at large. Moreover, they highlight the pressing need for additional research initiatives and targeted interventions aimed at enhancing outcomes and mitigating the burden imposed on both patients and the healthcare system.

This document is currently not available here.

Share

COinS
 
Apr 5th, 9:00 AM Apr 5th, 11:30 AM

Healthcare Utilization and Comorbidity Burden of Pancreatic Cancer in U.S Hospitals. Analysis of a National Sample Database

D.P. Culp Center Ballroom

Pancreatic cancer accounts for 3% of all cancer diagnoses in the United States and is the fourth leading cause of all cancer-related causes of death in the US according to the American Cancer Society in 2023, with 5 years survival rate ranging from 5-15%.This study aims to assess the economic burden and healthcare costs associated with the diagnosis, treatment, and management of pancreatic cancer, with a focus on understanding the financial impact on patients, healthcare systems, and society at large. A population-based cross-sectional study was conducted utilizing the National Inpatient Sample Database (NIS 2016-2020). The variable of interest, pancreatic cancer, was extracted employing the 10th edition of the International Classification of Diseases (ICD-10) as the primary diagnosis for hospitalization in US healthcare facilities. Covariates considered in this study encompassed patient socio-demographics such as age, gender, and race, alongside variables related to insurance type, total charges, and mortality outcome. To ensure the representativeness of the study population, weighting was applied to align it with the broader demographics of the U.S. populace. Estimations regarding disease-related healthcare costs, length of stay, and mortality were derived through both crude and Propensity-Matched Analyses. A sample size of 33,446 patients hospitalized with pancreatic cancer as the primary diagnosis upon admission was extracted from the database. Of these, 49.72% were female, and 50.23% were male. The average age at the time of pancreatic cancer diagnosis was 68.48 years (CI 68.36-68.61). Among the patients, 70.49% were covered by Medicare/Medicaid, 27.41% had private insurance, and 2.10% were self-pay patients. The average length of stay for newly diagnosed pancreatic cancer patients was 6.96 days (CI 6.89-7.03), with average total charges amounting to $89,561 (CI $88,131.09-$90,991.40) for Medicare/Medicaid patients, $90,566 (CI $88,117.15-$93,014.89) for those with private insurance, and $75,978 (CI $69,432.38-$82,523.69) for self-pay patients. Healthcare spending for pancreatic cancer increased by 26.13% from 2016 to 2020. In conclusion, our analysis of healthcare utilization and the comorbidity burden of pancreatic cancer in U.S. hospitals has unveiled valuable insights into the challenges encountered by both patients and healthcare systems. These findings underscore the significance of implementing tailored care strategies to effectively address the multifaceted economic impact of pancreatic cancer, not only on individual patients but also on society at large. Moreover, they highlight the pressing need for additional research initiatives and targeted interventions aimed at enhancing outcomes and mitigating the burden imposed on both patients and the healthcare system.